Cancer immunotherapy: a future paradigm shift in the treatment of non–small cell lung cancer

VK Anagnostou, JR Brahmer - Clinical Cancer Research, 2015 - AACR
Emerging evidence on the role of the antitumor activity of the immune system has generated
great interest in immunotherapy even for tumors that were historically considered as …

Cancer immunotherapy: A future paradigm shift in the treatment of non-small cell lung cancer

VK Anagnostou, JR Brahmer - Clinical Cancer Research, 2015 - pure.johnshopkins.edu
Emerging evidence on the role of the antitumor activity of the immune system has generated
great interest in immunotherapy even for tumors that were historically considered as …

Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer

VK Anagnostou, JR Brahmer - Clinical Cancer Research, 2015 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Emerging evidence on the role of the antitumor
activity of the immune system has generated great interest in immunotherapy even for …

Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.

VK Anagnostou, JR Brahmer - … Research: an Official Journal of the …, 2015 - europepmc.org
Emerging evidence on the role of the antitumor activity of the immune system has generated
great interest in immunotherapy even for tumors that were historically considered as …

[PDF][PDF] Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer

VK Anagnostou, JR Brahmer - Clin Cancer Res, 2015 - scholar.archive.org
Emerging evidence on the role of the antitumor activity of the immune system has generated
great interest in immunotherapy even for tumors that were historically considered as …

Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer

VK Anagnostou, JR Brahmer - … cancer research: an …, 2015 - pubmed.ncbi.nlm.nih.gov
Emerging evidence on the role of the antitumor activity of the immune system has generated
great interest in immunotherapy even for tumors that were historically considered as …